SCHEMBL1016068

SCHEMBL1016068

[CH2]Cc1cncnc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28157229 0.97
SCHEMBL451747 0.75
SCHEMBL6852160 0.75 ATM (0.50)
SCHEMBL12009180 0.73 CYP11B1 (0.48)
SCHEMBL1145814 0.69
SCHEMBL887237 0.69
SCHEMBL6263996 0.69
SCHEMBL1274793 0.69
SCHEMBL12700475 0.69
SCHEMBL26505 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106687457-A Heteroaryl compounds for kinase inhibition 阿里亚德医药股份有限公司 2017-05-17 CN claimed
EP-2091929-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS The European Molecular Biology Laboratory (DE) 2009-08-26 EP claimed
CN-101421257-A Agents that disrupt cellular replication and their use in inhibiting pathological conditions EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) 2009-04-29 CN claimed
WO-2007107352-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2007-09-27 WO claimed
EP-2478981-B1 SILVER-(CONJUGATED COMPOUND) COMPLEX SUMITOMO CHEMICAL CO (JP) 2020-12-23 EP disclosed
CN-110520413-A Big ring broad-spectrum antibiotic RQX PHARMACEUTICALS INC 2019-11-29 CN disclosed
CN-110506039-A Compounds and methods for targeted degradation of androgen receptor ARVINAS INC 2019-11-26 CN disclosed
CN-106458978-B Substituted piperidinyl tetrahydroquinolines and their use as α -2C adrenergic receptor antagonists 拜耳制药股份公司 2019-06-28 CN disclosed
CN-108727340-A Fluorine-substituted indazole compounds and application thereof 广东东阳光药业有限公司 2018-11-02 CN disclosed
CN-108738320-A 4- amino -2- (1H- pyrazolos [3 as the cGMP conditioning agents for treating angiocardiopathy, 4-b] pyridin-3-yl) -6- oxos -6,7- dihydro -5H- pyrrolo-es [2,3-d] pyrimidine derivatives and respective (1H- indazole -3- bases) derivative 默沙东公司 2018-11-02 CN disclosed
CN-108699048-A Oxadiazolamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same 株式会社钟根堂 2018-10-23 CN disclosed
CN-104926808-B Dihydropyrimidines and its application in drug 广东东阳光药业有限公司 2018-09-14 CN disclosed
US-6284748-B1 ANTIDIABETIC AGENT METABASIS THERAPEUTICS, INC. 2001-09-04 US disclosed
US-6040449-A USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT BANYU PHARMACEUTICAL CO LTD (JP) 2000-03-21 US disclosed
US-5948792-A POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. BANYU PHARMACEUTICAL CO., LTD. (JP) 1999-09-07 US disclosed
CN-1226888-A Fluorinated 1,4-disubstituted piperidine derivatives BANYU PHARMA CO LTD (JP) 1999-08-25 CN disclosed
EP-0930298-A1 FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1999-07-21 EP disclosed
US-4868185-A HYPOLIPIDEMIC, ANTICHOLESTEROL WARNER-LAMBERT COMPANY (US) 1989-09-19 US disclosed
EP-0105227-A1 Process for producing beta-lactam compounds, and intermediates useful for their production Sanraku Incorporated (JP) 1984-04-11 EP disclosed
EP-0040408-A1 Beta-lactam compounds and process for production thereof SANRAKU-OCEAN CO., LTD. (JP) 1981-11-25 EP disclosed